데이터 상품 상세검색

[의료]

바이오마커 데이터셋

바이오마커 데이터셋

  • 등록일2022-12-01
  • 조회수395
  • 다운로드190
  • 카테고리의료
  • 10

데이터 기본 이용료

  • 1,000,000원
상세정보
데이터등록일 데이터 수정일 데이터 이용기한 판매제공처
2022-12-01 2023-07-06 무기한 비네아
데이터 제공포맷 데이터 제공방식 데이터 파일용량 데이터 상품구분
json/zip 다운로드 440.00 KB dataset

● 데이터 상품명 바이오마커 데이터셋 ● 데이터 상품 부제 COVID-19의 임상 관련 바이오마커 데이터셋 ● 데이터 상품 요약 인용지수 상위 의학저널에 게재된 COVID-19의 바이오마커에 관련된 의학 학술논문 데이터 ● 키워드 데이터셋 상품 정보 ■ 상품 설명 및 특징 - 의학논문의 저자 키워드, 초록, 제목 등에서 추출한 키워드에 키워드 속성, 대역어, 키워드 출처, 논문 DOI, 저자, 발행연월, 논문URL, 저널명, 저널 ISSN, 발행기관, Impact Factor의 정보를 매핑한 데이터 ■ 컬럼(속성) 정보 - 키워드명: 키워드 - 키워드속성: 키워드 성격 - 키워드출처: 키워드 출현 위치 - 키워드대역어: 자체 보유 의학사전 및 구글번역기에 의한 대역어 - 논문DOI명: 키워드 출현 논문의 DOI - 논문제목: 키워드 출현 논문의 제목 - 논문저자: 키워드 출현 논문의 저자 - 논문발행연월: 키워드 출현 논문의 발행연월 - 논문초록: 키워드 출현 논문의 초록 - 논문URL: 키워드 출현 논문의 URL - 저널ISSN명: 키워드 출현 논문의 저널 ISSN - 저널제목: 키워드 출현 논문의 저널명 - 저널발행기관명: 키워드 출현 논문의 발행기관명 ● 연관 데이터셋 상품 정보 ■ 상품 설명 및 특징 - 특정 키워드의 연관 키워드를 co-occurrence기법과 Latent Semantic Algorithm에 의해 추출한 데이터셋 ■ 컬럼(속성) 정보 - 키워드명: 키워드 - 키워드속성: 키워드의 성격 - 연관키워드명: 키워드와 연관된 키워드 - 연관키워드 속성: 연관키워드의 속성 - 연관중요도: 동의여 여부와 동시출현수를 지표로 하는 중요도 ● 기간 및 범위 - 2014년 5월 ~ 2022년 12월 ● 활용 예제 - 특정 주제에 해당되는 키워드의 속성별, 저널별, 연도별, 저자별 추이 - 키워드의 연관어를 속성별, 저널별, 연도별, 저자별 분석

샘플정보
ID
카테고리ID
카테고리명
키워드명
키워드속성
대체키워드명
키워드출처
키워드대역어
논문ID
논문DOI명
논문제목
논문저자
논문발행연월
논문유형
논문출처
논문초록
논문URL
저널ID
저널ISSN명
저널제목
저널발행기관명
저널ImpactFactor명
103008 898 바이오마커 Subjective Term subjective abstract None 13781 10.1002/jpen.2318 High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19 Paula M Martins@@@Tatyanne L N Gomes@@@Emanoelly P Franco@@@Liana L Vieira@@@Gustavo D Pimentel 202208 Article PMC {{{ Abstract }}} !!{{ Background: }} Inflammation plays a crucial role in nutrition status and can be useful in early nutrition risk screening of patients during the coronavirus disease 2019 (COVID-19) pandemic. Thus, this study aimed to assess the association between systemic inflammatory markers and nutrition risk tools in intensive care unit (ICU) patients with COVID-19. !!{{ Methods: }} Patients with confirmed COVID-19 and ICU admission were enrolled in a retrospective, observational, cross-sectional study. The medians of C-reactive protein (CRP; ≥13.8 mg/dl) and the neutrophil-to-lymphocyte ratio (NLR; ≥12.6) upon admission were used to dichotomize patients. !!{{ Results: }} Of the 73 patients, 63% were men; the average age was 56 years, and the median length of hospital stay was 10 (25th: 4; 75th: 17) days. When nutrition risk screening tools were used, 85% were at risk according to Nutritional Risk Screening (≥3 points), whereas 42% had high risk according to the Modified Nutrition Risk in the Critically Ill (mNUTRIC; ≥5 points), and 57% were moderately or severely malnourished according to the Subjective Global Assessment (B or C). Mortality was higher in the group with NLR ≥12.6 than in the group with NLR <12.6, with no difference between CRP groups. A significant association was found only between NLR and mNUTRIC, even when adjusted by sex, age, and body mass index (odds ratio, 1.36; 95% CI, 1.06-1.76; P = 0.016), but not between CRP and nutrition risk. !!{{ Conclusion: }} Although the inflammatory marker CRP is the most used in hospital clinical practice, we found that only NLR was associated with nutrition risk (NUTRIC score). !!{{ Keywords: }} COVID-19; ICU; inflammation; nutrition status. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015430/ 910 0148-6071 JPEN. Journal of parenteral and enteral nutrition [Hoboken, NJ] : Wiley.
103009 898 바이오마커 systemic inflammatory marker Term systemic inflammatory marker abstract None 13781 10.1002/jpen.2318 High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19 Paula M Martins@@@Tatyanne L N Gomes@@@Emanoelly P Franco@@@Liana L Vieira@@@Gustavo D Pimentel 202208 Article PMC {{{ Abstract }}} !!{{ Background: }} Inflammation plays a crucial role in nutrition status and can be useful in early nutrition risk screening of patients during the coronavirus disease 2019 (COVID-19) pandemic. Thus, this study aimed to assess the association between systemic inflammatory markers and nutrition risk tools in intensive care unit (ICU) patients with COVID-19. !!{{ Methods: }} Patients with confirmed COVID-19 and ICU admission were enrolled in a retrospective, observational, cross-sectional study. The medians of C-reactive protein (CRP; ≥13.8 mg/dl) and the neutrophil-to-lymphocyte ratio (NLR; ≥12.6) upon admission were used to dichotomize patients. !!{{ Results: }} Of the 73 patients, 63% were men; the average age was 56 years, and the median length of hospital stay was 10 (25th: 4; 75th: 17) days. When nutrition risk screening tools were used, 85% were at risk according to Nutritional Risk Screening (≥3 points), whereas 42% had high risk according to the Modified Nutrition Risk in the Critically Ill (mNUTRIC; ≥5 points), and 57% were moderately or severely malnourished according to the Subjective Global Assessment (B or C). Mortality was higher in the group with NLR ≥12.6 than in the group with NLR <12.6, with no difference between CRP groups. A significant association was found only between NLR and mNUTRIC, even when adjusted by sex, age, and body mass index (odds ratio, 1.36; 95% CI, 1.06-1.76; P = 0.016), but not between CRP and nutrition risk. !!{{ Conclusion: }} Although the inflammatory marker CRP is the most used in hospital clinical practice, we found that only NLR was associated with nutrition risk (NUTRIC score). !!{{ Keywords: }} COVID-19; ICU; inflammation; nutrition status. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015430/ 910 0148-6071 JPEN. Journal of parenteral and enteral nutrition [Hoboken, NJ] : Wiley.
103010 898 바이오마커 systemic inflammatory markers Term systemic inflammatory marker abstract None 13781 10.1002/jpen.2318 High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19 Paula M Martins@@@Tatyanne L N Gomes@@@Emanoelly P Franco@@@Liana L Vieira@@@Gustavo D Pimentel 202208 Article PMC {{{ Abstract }}} !!{{ Background: }} Inflammation plays a crucial role in nutrition status and can be useful in early nutrition risk screening of patients during the coronavirus disease 2019 (COVID-19) pandemic. Thus, this study aimed to assess the association between systemic inflammatory markers and nutrition risk tools in intensive care unit (ICU) patients with COVID-19. !!{{ Methods: }} Patients with confirmed COVID-19 and ICU admission were enrolled in a retrospective, observational, cross-sectional study. The medians of C-reactive protein (CRP; ≥13.8 mg/dl) and the neutrophil-to-lymphocyte ratio (NLR; ≥12.6) upon admission were used to dichotomize patients. !!{{ Results: }} Of the 73 patients, 63% were men; the average age was 56 years, and the median length of hospital stay was 10 (25th: 4; 75th: 17) days. When nutrition risk screening tools were used, 85% were at risk according to Nutritional Risk Screening (≥3 points), whereas 42% had high risk according to the Modified Nutrition Risk in the Critically Ill (mNUTRIC; ≥5 points), and 57% were moderately or severely malnourished according to the Subjective Global Assessment (B or C). Mortality was higher in the group with NLR ≥12.6 than in the group with NLR <12.6, with no difference between CRP groups. A significant association was found only between NLR and mNUTRIC, even when adjusted by sex, age, and body mass index (odds ratio, 1.36; 95% CI, 1.06-1.76; P = 0.016), but not between CRP and nutrition risk. !!{{ Conclusion: }} Although the inflammatory marker CRP is the most used in hospital clinical practice, we found that only NLR was associated with nutrition risk (NUTRIC score). !!{{ Keywords: }} COVID-19; ICU; inflammation; nutrition status. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015430/ 910 0148-6071 JPEN. Journal of parenteral and enteral nutrition [Hoboken, NJ] : Wiley.
103564 898 바이오마커 predict Term predict abstract None 13792 10.1016/j.jtct.2022.02.018 B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Maxime Jullien@@@Amandine Le Bourgeois@@@Marianne Coste-Burel@@@Pierre Peterlin@@@Alice Garnier@@@Marie Rimbert@@@Berthe-Marie Imbert@@@Steven Le Gouill@@@Philippe Moreau@@@Beatrice Mahe@@@Viviane Dubruille@@@Nicolas Blin@@@Anne Lok@@@Cyrille Touzeau@@@Thomas Gastinne@@@Benoit Tessoulin@@@Sophie Vantyghem@@@Marie C B?n?@@@Thierry Guillaume@@@Patrice Chevallier 202205 Article PMC {{{ Abstract }}} !! Little is known about the immune response to SARS-CoV-2 vaccination in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, several studies have reported that adequate protection could be provided to this population. The purpose of this study was to evaluate which factors can predict the efficacy of SARS-CoV-2 vaccination in these specifically immunosuppressed patients. Specific anti-Spike (S) antibody responses were assessed in a cohort of 117 allo-HSCT recipients after 2 injections of BNT162b2 mRNA SARS-CoV-2 vaccine (V1 and V2). Factors considered liable to influence the antibody response and analyzed in this series were the interval between allo-HSCT and V1, donor source, recipient and donor age, current immunosuppressive/chemotherapy (I/C) treatment, and levels of CD4 + and CD8 + T cells, B cells, and natural killer cells at the time of V1. Overall, the S-antibody response rate, evaluated at a median of 35 days after V2, was 82.9% for the entire cohort, with 71 patients (61%) reaching the highest titer. In univariate analysis, a lower pre-V1 median total lymphocyte count, lower CD4 + T cell and B cell counts, ongoing I/C treatment, and a haploidentical donor were characteristic of nonhumoral responders. However, multiparameter analysis showed that B cell aplasia was the sole factor predicting the absence of a specific immune response (odds ratio, 0.01; 95% confidence interval, 0.00 to 0.10; P < 10 -3 ). Indeed, the rate of humoral response was 9.1% in patients with B cell aplasia versus 95.9% in patients with a B cell count >0 (P < 10 -9 ). These results advocate for the administration of anti-SARS-CoV-2 vaccination in allo-HSCT recipients as early as peripheral B cell levels can be detected, and also suggest the need for close monitoring of B-cell reconstitution after Allo-HSCT. !!{{ Keywords: }} Allogeneic; B cell; BNT162b2; COVID-19; Immune status; Lymphopenia; SARS-CoV-2 mRNA; Vaccine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865956/ 1138 2666-6375 Transplantation and cellular therapy [New York] : Elsevier Inc.
103158 898 바이오마커 accompanied Action accompanied abstract None 13785 10.1111/aor.14024 Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients Amir Ahmad Nassiri@@@Monir Sadat Hakemi@@@Mir Mohammad Miri@@@Reza Shahrami@@@Azadeh Ahmadi Koomleh@@@Tahereh Sabaghian 202111 Article PMC {{{ Abstract }}} !! Severe forms of the coronavirus disease 2019 (COVID-19) can progress to sepsis-like complications accompanied by cytokine storm for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID-19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID-19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre-, and post-treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C-reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO 2 /FiO 2 and overall organ function (ie, Sequential Organ Failure Assessment-SOFA score) also improved significantly. Patients stayed on the ICU for 9 days and 21 of them survived. To the best of our knowledge, this is one of the largest case series to date reporting early experiences on extracorporeal hemoadsorption therapy in SARS-CoV-2 positive patients with hyperinflammation and moderate ARDS. Treatment proved to be effective, technically feasible and well-tolerated. !!{{ Keywords: }} COVID-19; CytoSorb; hemoadsorption; hemodynamic; hyperinflammation; lung function. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444787/ 1280 0160-564X Artificial organs Cambridge, MA : Wiley-Blackwell.
103170 898 바이오마커 C-reactive protein Protein c-reactive protein abstract C-반응단백질 13785 10.1111/aor.14024 Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients Amir Ahmad Nassiri@@@Monir Sadat Hakemi@@@Mir Mohammad Miri@@@Reza Shahrami@@@Azadeh Ahmadi Koomleh@@@Tahereh Sabaghian 202111 Article PMC {{{ Abstract }}} !! Severe forms of the coronavirus disease 2019 (COVID-19) can progress to sepsis-like complications accompanied by cytokine storm for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID-19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID-19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre-, and post-treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C-reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO 2 /FiO 2 and overall organ function (ie, Sequential Organ Failure Assessment-SOFA score) also improved significantly. Patients stayed on the ICU for 9 days and 21 of them survived. To the best of our knowledge, this is one of the largest case series to date reporting early experiences on extracorporeal hemoadsorption therapy in SARS-CoV-2 positive patients with hyperinflammation and moderate ARDS. Treatment proved to be effective, technically feasible and well-tolerated. !!{{ Keywords: }} COVID-19; CytoSorb; hemoadsorption; hemodynamic; hyperinflammation; lung function. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444787/ 1280 0160-564X Artificial organs Cambridge, MA : Wiley-Blackwell.
103011 898 바이오마커 the median Term the median abstract None 13781 10.1002/jpen.2318 High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19 Paula M Martins@@@Tatyanne L N Gomes@@@Emanoelly P Franco@@@Liana L Vieira@@@Gustavo D Pimentel 202208 Article PMC {{{ Abstract }}} !!{{ Background: }} Inflammation plays a crucial role in nutrition status and can be useful in early nutrition risk screening of patients during the coronavirus disease 2019 (COVID-19) pandemic. Thus, this study aimed to assess the association between systemic inflammatory markers and nutrition risk tools in intensive care unit (ICU) patients with COVID-19. !!{{ Methods: }} Patients with confirmed COVID-19 and ICU admission were enrolled in a retrospective, observational, cross-sectional study. The medians of C-reactive protein (CRP; ≥13.8 mg/dl) and the neutrophil-to-lymphocyte ratio (NLR; ≥12.6) upon admission were used to dichotomize patients. !!{{ Results: }} Of the 73 patients, 63% were men; the average age was 56 years, and the median length of hospital stay was 10 (25th: 4; 75th: 17) days. When nutrition risk screening tools were used, 85% were at risk according to Nutritional Risk Screening (≥3 points), whereas 42% had high risk according to the Modified Nutrition Risk in the Critically Ill (mNUTRIC; ≥5 points), and 57% were moderately or severely malnourished according to the Subjective Global Assessment (B or C). Mortality was higher in the group with NLR ≥12.6 than in the group with NLR <12.6, with no difference between CRP groups. A significant association was found only between NLR and mNUTRIC, even when adjusted by sex, age, and body mass index (odds ratio, 1.36; 95% CI, 1.06-1.76; P = 0.016), but not between CRP and nutrition risk. !!{{ Conclusion: }} Although the inflammatory marker CRP is the most used in hospital clinical practice, we found that only NLR was associated with nutrition risk (NUTRIC score). !!{{ Keywords: }} COVID-19; ICU; inflammation; nutrition status. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015430/ 910 0148-6071 JPEN. Journal of parenteral and enteral nutrition [Hoboken, NJ] : Wiley.
103544 898 바이오마커 HSCT Term hsct abstract None 13792 10.1016/j.jtct.2022.02.018 B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Maxime Jullien@@@Amandine Le Bourgeois@@@Marianne Coste-Burel@@@Pierre Peterlin@@@Alice Garnier@@@Marie Rimbert@@@Berthe-Marie Imbert@@@Steven Le Gouill@@@Philippe Moreau@@@Beatrice Mahe@@@Viviane Dubruille@@@Nicolas Blin@@@Anne Lok@@@Cyrille Touzeau@@@Thomas Gastinne@@@Benoit Tessoulin@@@Sophie Vantyghem@@@Marie C B?n?@@@Thierry Guillaume@@@Patrice Chevallier 202205 Article PMC {{{ Abstract }}} !! Little is known about the immune response to SARS-CoV-2 vaccination in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, several studies have reported that adequate protection could be provided to this population. The purpose of this study was to evaluate which factors can predict the efficacy of SARS-CoV-2 vaccination in these specifically immunosuppressed patients. Specific anti-Spike (S) antibody responses were assessed in a cohort of 117 allo-HSCT recipients after 2 injections of BNT162b2 mRNA SARS-CoV-2 vaccine (V1 and V2). Factors considered liable to influence the antibody response and analyzed in this series were the interval between allo-HSCT and V1, donor source, recipient and donor age, current immunosuppressive/chemotherapy (I/C) treatment, and levels of CD4 + and CD8 + T cells, B cells, and natural killer cells at the time of V1. Overall, the S-antibody response rate, evaluated at a median of 35 days after V2, was 82.9% for the entire cohort, with 71 patients (61%) reaching the highest titer. In univariate analysis, a lower pre-V1 median total lymphocyte count, lower CD4 + T cell and B cell counts, ongoing I/C treatment, and a haploidentical donor were characteristic of nonhumoral responders. However, multiparameter analysis showed that B cell aplasia was the sole factor predicting the absence of a specific immune response (odds ratio, 0.01; 95% confidence interval, 0.00 to 0.10; P < 10 -3 ). Indeed, the rate of humoral response was 9.1% in patients with B cell aplasia versus 95.9% in patients with a B cell count >0 (P < 10 -9 ). These results advocate for the administration of anti-SARS-CoV-2 vaccination in allo-HSCT recipients as early as peripheral B cell levels can be detected, and also suggest the need for close monitoring of B-cell reconstitution after Allo-HSCT. !!{{ Keywords: }} Allogeneic; B cell; BNT162b2; COVID-19; Immune status; Lymphopenia; SARS-CoV-2 mRNA; Vaccine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865956/ 1138 2666-6375 Transplantation and cellular therapy [New York] : Elsevier Inc.
103012 898 바이오마커 were used Action were used abstract None 13781 10.1002/jpen.2318 High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19 Paula M Martins@@@Tatyanne L N Gomes@@@Emanoelly P Franco@@@Liana L Vieira@@@Gustavo D Pimentel 202208 Article PMC {{{ Abstract }}} !!{{ Background: }} Inflammation plays a crucial role in nutrition status and can be useful in early nutrition risk screening of patients during the coronavirus disease 2019 (COVID-19) pandemic. Thus, this study aimed to assess the association between systemic inflammatory markers and nutrition risk tools in intensive care unit (ICU) patients with COVID-19. !!{{ Methods: }} Patients with confirmed COVID-19 and ICU admission were enrolled in a retrospective, observational, cross-sectional study. The medians of C-reactive protein (CRP; ≥13.8 mg/dl) and the neutrophil-to-lymphocyte ratio (NLR; ≥12.6) upon admission were used to dichotomize patients. !!{{ Results: }} Of the 73 patients, 63% were men; the average age was 56 years, and the median length of hospital stay was 10 (25th: 4; 75th: 17) days. When nutrition risk screening tools were used, 85% were at risk according to Nutritional Risk Screening (≥3 points), whereas 42% had high risk according to the Modified Nutrition Risk in the Critically Ill (mNUTRIC; ≥5 points), and 57% were moderately or severely malnourished according to the Subjective Global Assessment (B or C). Mortality was higher in the group with NLR ≥12.6 than in the group with NLR <12.6, with no difference between CRP groups. A significant association was found only between NLR and mNUTRIC, even when adjusted by sex, age, and body mass index (odds ratio, 1.36; 95% CI, 1.06-1.76; P = 0.016), but not between CRP and nutrition risk. !!{{ Conclusion: }} Although the inflammatory marker CRP is the most used in hospital clinical practice, we found that only NLR was associated with nutrition risk (NUTRIC score). !!{{ Keywords: }} COVID-19; ICU; inflammation; nutrition status. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015430/ 910 0148-6071 JPEN. Journal of parenteral and enteral nutrition [Hoboken, NJ] : Wiley.
103013 898 바이오마커 95% CI Term 95% CI abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103159 898 바이오마커 acute respiratory distress Symptom acute respiratory distress abstract None 13785 10.1111/aor.14024 Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients Amir Ahmad Nassiri@@@Monir Sadat Hakemi@@@Mir Mohammad Miri@@@Reza Shahrami@@@Azadeh Ahmadi Koomleh@@@Tahereh Sabaghian 202111 Article PMC {{{ Abstract }}} !! Severe forms of the coronavirus disease 2019 (COVID-19) can progress to sepsis-like complications accompanied by cytokine storm for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID-19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID-19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre-, and post-treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C-reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO 2 /FiO 2 and overall organ function (ie, Sequential Organ Failure Assessment-SOFA score) also improved significantly. Patients stayed on the ICU for 9 days and 21 of them survived. To the best of our knowledge, this is one of the largest case series to date reporting early experiences on extracorporeal hemoadsorption therapy in SARS-CoV-2 positive patients with hyperinflammation and moderate ARDS. Treatment proved to be effective, technically feasible and well-tolerated. !!{{ Keywords: }} COVID-19; CytoSorb; hemoadsorption; hemodynamic; hyperinflammation; lung function. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444787/ 1280 0160-564X Artificial organs Cambridge, MA : Wiley-Blackwell.
103160 898 바이오마커 acute respiratory distress syndrome Disease acute respiratory distress syndrome abstract 급성 호흡기 장애 증후군 13785 10.1111/aor.14024 Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients Amir Ahmad Nassiri@@@Monir Sadat Hakemi@@@Mir Mohammad Miri@@@Reza Shahrami@@@Azadeh Ahmadi Koomleh@@@Tahereh Sabaghian 202111 Article PMC {{{ Abstract }}} !! Severe forms of the coronavirus disease 2019 (COVID-19) can progress to sepsis-like complications accompanied by cytokine storm for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID-19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID-19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre-, and post-treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C-reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO 2 /FiO 2 and overall organ function (ie, Sequential Organ Failure Assessment-SOFA score) also improved significantly. Patients stayed on the ICU for 9 days and 21 of them survived. To the best of our knowledge, this is one of the largest case series to date reporting early experiences on extracorporeal hemoadsorption therapy in SARS-CoV-2 positive patients with hyperinflammation and moderate ARDS. Treatment proved to be effective, technically feasible and well-tolerated. !!{{ Keywords: }} COVID-19; CytoSorb; hemoadsorption; hemodynamic; hyperinflammation; lung function. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444787/ 1280 0160-564X Artificial organs Cambridge, MA : Wiley-Blackwell.
103014 898 바이오마커 analyzed Action analyzed abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103015 898 바이오마커 Biomarker Term biomarker abstract 바이오마커 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103648 898 바이오마커 venous Term venous abstract abnormality 13793 10.1016/j.jvsv.2020.07.009 Utility of d-dimer for diagnosis of deep vein thrombosis in coronavirus disease-19 infection Edward S Cho@@@Paul H McClelland@@@Olivia Cheng@@@Yuri Kim@@@James Hu@@@Michael E Zenilman@@@Marcus D'Ayala 202101 Article PMC {{{ Abstract }}} !!{{ Objective: }} The objective of this study was to investigate the clinical usefulness of d-dimer in excluding a diagnosis of deep vein thrombosis (DVT) in patients with coronavirus disease (COVID-19) infection, potentially limiting the need for venous duplex ultrasound examination. !!{{ Methods: }} We retrospectively reviewed consecutive patients admitted to our institution with confirmed COVID-19 status by polymerase chain reaction between March 1, 2020, and May 13, 2020, and selected those who underwent both d-dimer and venous duplex ultrasound examination. This cohort was divided into two groups, those with and without DVT based on duplex ultrasound examination. These groups were then compared to determine the value of d-dimer in establishing this diagnosis. !!{{ Results: }} A total of 1170 patients were admitted with COVID-19, of which 158 were selected for this study. Of the 158, there were 52 patients with DVT and 106 without DVT. There were no differences in sex, age, race, or ethnicity between groups. Diabetes and routine hemodialysis were less commonly seen in the group with DVT. More than 90% of patients in both groups received prophylactic anticoagulation, but the use of low-molecular-weight heparin or subcutaneous heparin prophylaxis was not predictive of DVT. All patients had elevated acute-phase d-dimer levels using conventional criteria, and 154 of the 158 (97.5%) had elevated levels with age-adjusted criteria (mean d-dimer 16,163 ± 5395 ng/mL). Those with DVT had higher acute-phase d-dimer levels than those without DVT (median, 13,602 [interquartile range, 6616-36,543 ng/mL] vs 2880 [interquartile range, 1030-9126 ng/mL], P < .001). An optimal d-dimer cutoff of 6494 ng/mL was determined to differentiate those with and without DVT (sensitivity 80.8%, specificity 68.9%, negative predictive value 88.0%). Wells DVT criteria was not found to be a significant predictor of DVT. Elevated d-dimer as defined by our optimal metric was a statistically significant predictor of DVT in both univariate and multivariable analyses when adjusting for other factors (odds ratio, 6.12; 95% confidence interval, 2.79-13.39; P < .001). !!{{ Conclusions: }} d-dimer levels are uniformly elevated in patients with COVID-19. Although standard predictive criteria failed to predict DVT, our analysis showed a d-dimer of less than 6494 ng/mL may exclude DVT, potentially limiting the need for venous duplex ultrasound examination. !!{{ Keywords: }} COVID-19; D-dimer; Deep vein thrombosis; Wells DVT criteria. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390766/ 1271 2213-333X Journal of vascular surgery. Venous and lymphatic New York, NY : Elsevier Inc.
103092 898 바이오마커 Admission Term admission abstract 입장료 13783 10.1007/s11739-021-02637-8 Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study Tyler Pitre@@@Aaron Jones@@@Johnny Su@@@Wryan Helmeczi@@@Grace Xu@@@Catherine Lee@@@Adib Shamsuddin@@@Adhora Mir@@@Sarah MacGregor@@@MyLinh Duong@@@Terence Ho@@@Marla K Beauchamp@@@Andrew P Costa@@@Rebecca Kruisselbrink@@@COREG Investigators 202109 Article PMC {{{ Abstract }}} !! Inflammatory biomarkers may be associated with disease severity and increased mortality in COVID-19 patients but have not been studied in North American populations. We sought to determine whether a set of commonly ordered inflammatory biomarkers can predict 28-day mortality. We analyzed a multi-centered (four) COVID-19 registry cohort from March 4th to December 7th, 2020. This cohort included COVID-19-positive patients admitted to medical wards or intensive care units. Patients presenting to the emergency department for COVID-19 symptoms and then subsequently discharged were also included. We performed Cox-regression analysis to measure whether commonly used biomarkers were associated with an increased 28-day mortality. Of 336 COVID-19-positive patients, 267 required hospital admission, and 69 were seen in the emergency room and discharged. The median age was 63 years (IQR 80-50) and the female-to-male ratio was 49:51. Derivation of internally validated cut-offs suggested that C-reactive protein ≥ 78.4 mg/L, neutrophil-to-lymphocyte ratio ≥ 6.1, lymphocyte-to-white blood cell ratio < 0.127, and a modified Glasgow prognostic score equal to 2 vs. 1 or 0 were associated with the highest increased risk of 28-day mortality. We provide early estimates of cut-off values for inflammatory biomarkers and indices measured at the time of admission that may be useful to clinicians for predicting 28-day mortality in North American COVID-19 patients. !!{{ Keywords: }} Biomarkers; COVID-19; CRP; NLR; mGPS. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836340/ 173 1828-0447 Internal and Emergency Medicine Milan : Springer.
103161 898 바이오마커 ARDS Disease ard abstract 성 호흡곤란 증후군 13785 10.1111/aor.14024 Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients Amir Ahmad Nassiri@@@Monir Sadat Hakemi@@@Mir Mohammad Miri@@@Reza Shahrami@@@Azadeh Ahmadi Koomleh@@@Tahereh Sabaghian 202111 Article PMC {{{ Abstract }}} !! Severe forms of the coronavirus disease 2019 (COVID-19) can progress to sepsis-like complications accompanied by cytokine storm for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID-19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID-19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre-, and post-treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C-reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO 2 /FiO 2 and overall organ function (ie, Sequential Organ Failure Assessment-SOFA score) also improved significantly. Patients stayed on the ICU for 9 days and 21 of them survived. To the best of our knowledge, this is one of the largest case series to date reporting early experiences on extracorporeal hemoadsorption therapy in SARS-CoV-2 positive patients with hyperinflammation and moderate ARDS. Treatment proved to be effective, technically feasible and well-tolerated. !!{{ Keywords: }} COVID-19; CytoSorb; hemoadsorption; hemodynamic; hyperinflammation; lung function. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444787/ 1280 0160-564X Artificial organs Cambridge, MA : Wiley-Blackwell.
103162 898 바이오마커 best Compound best abstract None 13785 10.1111/aor.14024 Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients Amir Ahmad Nassiri@@@Monir Sadat Hakemi@@@Mir Mohammad Miri@@@Reza Shahrami@@@Azadeh Ahmadi Koomleh@@@Tahereh Sabaghian 202111 Article PMC {{{ Abstract }}} !! Severe forms of the coronavirus disease 2019 (COVID-19) can progress to sepsis-like complications accompanied by cytokine storm for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID-19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID-19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre-, and post-treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C-reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO 2 /FiO 2 and overall organ function (ie, Sequential Organ Failure Assessment-SOFA score) also improved significantly. Patients stayed on the ICU for 9 days and 21 of them survived. To the best of our knowledge, this is one of the largest case series to date reporting early experiences on extracorporeal hemoadsorption therapy in SARS-CoV-2 positive patients with hyperinflammation and moderate ARDS. Treatment proved to be effective, technically feasible and well-tolerated. !!{{ Keywords: }} COVID-19; CytoSorb; hemoadsorption; hemodynamic; hyperinflammation; lung function. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444787/ 1280 0160-564X Artificial organs Cambridge, MA : Wiley-Blackwell.
103840 898 바이오마커 examined Action examined abstract None 13797 10.1007/s11239-021-02405-7 Can a modified-simplified pulmonary embolism severity index (m-sPESI) be used to predict the need for intensive care in hospitalized COVID-19 patients? Ahmet Kagan As@@@Burak Erdolu@@@Burak Duman@@@Elif Yazgan@@@Cuneyt Eris@@@Ufuk Aydin@@@Yusuf Ata@@@Ozlem Sengoren Dikis@@@Tamer T?rk 202110 Article PMC {{{ Abstract }}} !! Severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has been considered a pandemic by the World Health Organization (WHO). Clinical manifestations of COVID-19 disease may differ, most cases are mild, but a significant minority of patients may develop moderate to severe respiratory symptoms, with the most severe cases requiring intensive care and/or mechanical ventilatory support. In this study, we aimed to identify validity of our modified scoring system for foreseeing the approach to the COVID-19 patient and the disease, the treatment plan, the severity of morbidity and even the risk of mortality from the clinician's point of view. In this single center study, we examined the patients hospitalized with the diagnosis of COVID-19 between 01/04/2020 and 01/06/2020, of the 228 patients who were between 20 and 90 years of age, and whose polymerase chain reaction (PCR) tests of nasal and pharyngeal swab samples were positive. We evaulated 228 (92 male and 136 female) PCR (+) patients. Univariate analysis showed that advanced age (p < 0.001), hemoglobin (p < 0.001), troponin-I (p < 0.001), C-reactive protein (CRP) (p < 0.001), fibrinogen (p < 0.001), HT (p = 0.01), CAD (p = 0.001), DM (p < 0.001), history of malignancy (p = 0.008), along with m-sPESI scores (p < 0.001) were significantly higher in patients that needed intensive care due to COVID-19 infection. In the multivariable logistic regression analysis, only the m-sPESI score higher than ≥ 2 was found to be highly significant in terms of indicating the need for ICU admission (AUC 0.948; 84.6% sensitivity and 94.6% specificity) (p < 0.001). With an increasing number of hospitalized patients, healthcare providers are confronting a deluge of lab results in the process of caring for COVID-19 patients. It is imperative to identify risk factors for mortality and morbidity development. The modified sPESI scoring system, which we put forward, is successful in predicting the course of the disease at the presentation of the patient with COVID-19 disease and predicting the need for intensive care with high specificity and sensitivity, can detect the need for intensive care with high specificity and sensitivity. !!{{ Keywords: }} Covid-19; Intensive care unit; PESI; Pulmonary thromboembolism; SPESI; Thrombosis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952498/ 79 0929-5305 Journal of Thrombosis and Thrombolysis [Dordrecht ; Norwell, MA] : Kluwer Academic Publishers
103016 898 바이오마커 clinical study Term clinical study title None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103017 898 바이오마커 conducted Action conducted abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103018 898 바이오마커 contributing to Action contributing to abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103019 898 바이오마커 controls Term control abstract abnormality 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103020 898 바이오마커 coronavirus Virus coronavirus abstract 코로나바이러스 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103021 898 바이오마커 coronavirus disease Disease coronavirus disease abstract 코로나바이러스 질환 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103022 898 바이오마커 coronavirus disease-2019 Term coronavirus disease-2019 author 코로나바이러스 질병 2019 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
183785 898 바이오마커 Invasive mechanical ventilation Treatment invasive mechanical ventilation abstract None 78012 10.1080/07315724.2021.1951891 Association between Vitamin D Status and Risk of Developing Severe COVID-19 Infection: A Meta-Analysis of Observational Studies Mohamed Ben-Eltriki@@@Robert Hopefl@@@James M Wright@@@Subrata Deb 202209 Article PMC {{{ Abstract }}} !!{{ Objective: }} The relationship between 25-hydroxyvitamin D3 (25(OH)D), the surrogate marker for vitamin D 3 , serum concentration and COVID-19 has come to the forefront as a potential pathway to improve COVID-19 outcomes. The current evidence remains unclear on the impact of vitamin D status on the severity and outcomes of COVID-19 infection. To explore possible association between low 25(OH)D levels and risk of developing severe COVID-19 (i.e. need for invasive mechanical ventilation, the length of hospital stay, total deaths). We also aimed to understand the relationship between vitamin D insufficiency and elevated inflammatory and cardiac biomarkers. !!{{ Methods: }} We conducted a comprehensive electronic literature search for any original research study published up to March 30, 2021. For the purpose of this review, low vitamin D status was defined as a range of serum total 25(OH)D levels of <10 to <30 ng/ml. Two independent investigators assessed study eligibility, synthesized evidence, analyzed, critically examined, and interpreted herein. !!{{ Results: }} Twenty-four observational studies containing 3637 participants were included in the meta-analysis. The mean age of the patients was 61.1 years old; 56% were male. Low vitamin D status was statistically associated with higher risk of death (RR, 1.60 (95% CI, 1.10-2.32), higher risk of developing severe COVID-19 pneumonia (RR: 1.50; 95% CI, 1.10-2.05). COVID-19 patients with low vitamin D levels had a greater prevalence of hypertension and cardiovascular diseases, abnormally high serum troponin and peak D-dimer levels, as well as elevated interleukin-6 and C-reactive protein than those with serum 25(OH)D levels ≥30 ng/ml. !!{{ Conclusions: }} In this meta-analysis, we found a potential increased risk of developing severe COVID-19 infection among patients with low vitamin D levels. There are plausible biological mechanisms supporting the role of vitamin D in COVID-19 severity. Randomized controlled trials are needed to test for potential beneficial effects of vitamin D in COVID-19 outcomes. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425440/ 1317 2769-7061 Journal of the American Nutrition Association Philadelphia, Pennsylvania : Taylor & Francis
184374 898 바이오마커 drug target Term drug target abstract 약물 목표 78025 10.3389/fimmu.2022.1013322 IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA Qingcong Zheng@@@Du Wang@@@Rongjie Lin@@@Qi Lv@@@Wanming Wang 202209 Article PMC {{{ Abstract }}} !!{{ Background: }} Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic of severe coronavirus disease 2019 (COVID-19). Staphylococcus aureus is one of the most common pathogenic bacteria in humans, rheumatoid arthritis (RA) is among the most prevalent autoimmune conditions. RA is a significant risk factor for SARS-CoV-2 and S. aureus infections, although the mechanism of RA and SARS-CoV-2 infection in conjunction with S. aureus infection has not been elucidated. The purpose of this study is to investigate the biomarkers and disease targets between RA and SARS-CoV-2 and S. aureus infections using bioinformatics analysis, to search for the molecular mechanisms of SARS-CoV-2 and S. aureus immune escape and potential drug targets in the RA population, and to provide new directions for further analysis and targeted development of clinical treatments. !!{{ Methods: }} The RA dataset (GSE93272) and the S. aureus bacteremia (SAB) dataset (GSE33341) were used to obtain differentially expressed gene sets, respectively, and the common differentially expressed genes (DEGs) were determined through the intersection. Functional enrichment analysis utilizing GO, KEGG, and ClueGO methods. The PPI network was created utilizing the STRING database, and the top 10 hub genes were identified and further examined for functional enrichment using Metascape and GeneMANIA. The top 10 hub genes were intersected with the SARS-CoV-2 gene pool to identify five hub genes shared by RA, COVID-19, and SAB, and functional enrichment analysis was conducted using Metascape and GeneMANIA. Using the NetworkAnalyst platform, TF-hub gene and miRNA-hub gene networks were built for these five hub genes. The hub gene was verified utilizing GSE17755, GSE55235, and GSE13670, and its effectiveness was assessed utilizing ROC curves. CIBERSORT was applied to examine immune cell infiltration and the link between the hub gene and immune cells. !!{{ Results: }} A total of 199 DEGs were extracted from the GSE93272 and GSE33341 datasets. KEGG analysis of enrichment pathways were NLR signaling pathway, cell membrane DNA sensing pathway, oxidative phosphorylation, and viral infection. Positive/negative regulation of the immune system, regulation of the interferon-I (IFN-I; IFN-α/β) pathway, and associated pathways of the immunological response to viruses were enriched in GO and ClueGO analyses. PPI network and Cytoscape platform identified the top 10 hub genes: RSAD2, IFIT3, GBP1, RTP4, IFI44, OAS1, IFI44L, ISG15, HERC5, and IFIT5. The pathways are mainly enriched in response to viral and bacterial infection, IFN signaling, and 1,25-dihydroxy vitamin D3. IFI44, OAS1, IFI44L, ISG15, and HERC5 are the five hub genes shared by RA, COVID-19, and SAB. The pathways are primarily enriched for response to viral and bacterial infections. The TF-hub gene network and miRNA-hub gene network identified YY1 as a key TF and hsa-mir-1-3p and hsa-mir-146a-5p as two important miRNAs related to IFI44. IFI44 was identified as a hub gene by validating GSE17755, GSE55235, and GSE13670. Immune cell infiltration analysis showed a strong positive correlation between activated dendritic cells and IFI44 expression. !!{{ Conclusions: }} IFI144 was discovered as a shared biomarker and disease target for RA, COVID-19, and SAB by this study. IFI44 negatively regulates the IFN signaling pathway to promote viral replication and bacterial proliferation and is an important molecular target for SARS-CoV-2 and S. aureus immune escape in RA. Dendritic cells play an important role in this process. 1,25-Dihydroxy vitamin D3 may be an important therapeutic agent in treating RA with SARS-CoV-2 and S. aureus infections. !!{{ Keywords: }} 1,25-dihydroxy vitamin D3; COVID-19; IFI44; Rheumatoid arthritis; SARS-CoV-2; Staphylococcus aureus; dendritic cells. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520788/ 109 1664-3224 Frontiers in Immunology [Lausanne : Frontiers Research Foundation].
183705 898 바이오마커 White blood cells Cell white blood cell abstract None 78010 10.1371/journal.pone.0275745 Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients Tomohito Gohda@@@Maki Murakoshi@@@Yusuke Suzuki@@@Makoto Hiki@@@Toshio Naito@@@Kazuhisa Takahashi@@@Yoko Tabe 202210 Article PMC {{{ Abstract }}} !!{{ Background: }} Although hyperinflammatory response influences the severity of coronavirus disease 2019 (COVID-19), little has been reported about the utility of tumor necrosis factor (TNF)-related biomarkers in reflecting the prognosis. We examined whether TNF receptors (TNFRs: TNFR1, TNFR2) and progranulin (PGRN) levels, in addition to interleukin 6 (IL-6) and C-reactive protein (CRP), are associated with mortality or disease severity in COVID-19 patients. !!{{ Methods: }} This retrospective study was conducted at Juntendo University Hospital. Eighty hospitalized patients with various severities of COVID-19 were enrolled. Furthermore, serum levels of TNF-related biomarkers were measured using enzyme-linked immunosorbent assay. !!{{ Results: }} Twenty-five patients died during hospitalization, and 55 were discharged. The median (25th and 75th percentiles) age of the study patients was 70 (61-76) years, 44 (55.0%) patients were males, and 26 (32.5%) patients had chronic kidney disease (CKD). When comparing with patients who received and did not receive treatment at the intensive care unit (ICU), the former had a higher tendency of being male and have diabetes, hypertension, and CKD; had higher levels of white blood cells, D-dimer, and lactate dehydrogenase; and had lower body mass index, estimated glomerular filtration rate, and lymphocyte counts. Significant differences were observed in TNFR, PGRN, IL-6, and CRP levels between each severity (mild-severe) group. Furthermore, the serum levels of TNFR, IL-6, and CRP, but not PGRN, in ICU patients were significantly higher than in the patients who were not admitted to the ICU. Multivariate logistic regression analysis demonstrated that high levels of TNFR2 were only associated with mortality in patients with COVID-19 even after adjustment for relevant clinical parameters. !!{{ Conclusions: }} High TNFR2 level might be helpful for predicting mortality or disease severity in patients with COVID-19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553057/ 49 1932-6203 PLoS ONE San Francisco, CA : Public Library of Science.
103023 898 바이오마커 COVID-19 Disease covid-19 author 코로나-19 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103024 898 바이오마커 Disease progression Term disease progression abstract 병 진행 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103025 898 바이오마커 Diseases Disease disease abstract 질환 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103026 898 바이오마커 disease severity Term disease severity abstract 질병 심각성 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103027 898 바이오마커 effect size Term effect size abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103028 898 바이오마커 elevated Action elevated abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103029 898 바이오마커 eligible Term eligible abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103030 898 바이오마커 evaluate Action evaluate abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103031 898 바이오마커 Evidence Term evidence abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103032 898 바이오마커 expressed Action expressed title,abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103033 898 바이오마커 expression Action expression abstract 표현 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103034 898 바이오마커 Google Scholar Term google scholar abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103035 898 바이오마커 healthy Action healthy abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103036 898 바이오마커 healthy control Patient healthy control abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103037 898 바이오마커 healthy controls Patient healthy control abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103038 898 바이오마커 healthy individuals Patient healthy individual abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103039 898 바이오마커 Human Term human abstract 인간 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103040 898 바이오마커 immune response Action immune response abstract 면역 반응 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103041 898 바이오마커 infected patient Patient infected patient abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103042 898 바이오마커 infected patients Patient infected patient abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103043 898 바이오마커 Infection Symptom infection abstract 감염 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103044 898 바이오마커 infections Symptom infection abstract 감염 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103045 898 바이오마커 Inflammatory Term inflammatory abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103046 898 바이오마커 item Term item abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103047 898 바이오마커 marker Term marker abstract 표지 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
38095 898 바이오마커 IL-8 Protein il-8 abstract 인터루킨-8 2113 10.1016/j.ebiom.2021.103378 Clinical features and prognostic factors in Covid-19: A prospective cohort study 202105 Multicenter Study PMC Background Mortality rates are high among hospitalized patients with COVID-19, especially in those intubated on the ICU. Insight in pathways associated with unfavourable outcome may lead to new treatment strategies. Methods We performed a prospective cohort study of patients with COVID-19 admitted to general ward or ICU who underwent serial blood sampling. To provide insight in the pathways involved in disease progression, associations were estimated between outcome risk and serial measurements of 64 biomarkers in potential important pathways of COVID-19 infection (inflammation, tissue damage, complement system, coagulation and fibrinolysis) using joint models combining Cox regression and linear mixed-effects models. For patients admitted to the general ward, the primary outcome was admission to the ICU or mortality (unfavourable outcome). For patients admitted to the ICU, the primary outcome was 12-week mortality. Findings A total of 219 patients were included: 136 (62%) on the ward and 119 patients (54%) on the ICU; 36 patients (26%) were included in both cohorts because they were transferred from general ward to ICU. On the general ward, 54 of 136 patients (40%) had an unfavourable outcome and 31 (23%) patients died. On the ICU, 54 out of 119 patients (45%) died. Unfavourable outcome on the general ward was associated with changes in concentrations of IL-6, IL-8, IL-10, soluble Receptor for Advanced Glycation End Products (sRAGE), vascular cell adhesion molecule 1 (VCAM-1) and Pentraxin-3. Death on the ICU was associated with changes in IL-6, IL-8, IL-10, sRAGE, VCAM-1, Pentraxin-3, urokinase-type plasminogen activator receptor, IL-1-receptor antagonist, CD14, procalcitonin, tumor necrosis factor alfa, tissue factor, complement component 5a, Growth arrest?specific 6, angiopoietin 2, and lactoferrin. Pathway analysis showed that unfavourable outcome on the ward was mainly driven by chemotaxis and interleukin production, whereas death on ICU was associated with a variety of pathways including chemotaxis, cell-cell adhesion, innate host response mechanisms, including the complement system, viral life cycle regulation, angiogenesis, wound healing and response to corticosteroids. Interpretation Clinical deterioration in patients with severe COVID-19 involves multiple pathways, including chemotaxis and interleukin production, but also endothelial dysfunction, the complement system, and immunothrombosis. Prognostic markers showed considerable overlap between general ward and ICU patients, but we identified distinct differences between groups that should be considered in the development and timing of interventional therapies in COVID-19. Funding Amsterdam UMC, Amsterdam UMC Corona Fund, and Dr. C.J. Vaillant Fonds. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118723/ 110 2352-3964 EBioMedicine [Amsterdam] : Elsevier B.V.
103048 898 바이오마커 material Term material abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103049 898 바이오마커 Meta-analysis Term meta-analysis abstract 메타분석 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103050 898 바이오마커 Mild-to-moderate Term mild-to-moderate abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103051 898 바이오마커 Mortality Term mortality abstract 치사성 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103052 898 바이오마커 myeloid cells Cell myeloid cell abstract 골수세포 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103053 898 바이오마커 myeloid cells-1 Term myeloid cells-1 abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103054 898 바이오마커 no differences Action no difference abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103055 898 바이오마커 observational studies Term observational study abstract 관찰 연구 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103056 898 바이오마커 observational study Term observational study abstract 관찰연구 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103057 898 바이오마커 outcome Term outcome abstract 결과 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103058 898 바이오마커 Patient Term patient abstract 환자 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103059 898 바이오마커 patients with COVID-19 Patient patients with COVID-19 abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103060 898 바이오마커 performed Action performed abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103061 898 바이오마커 Pneumonia Disease pneumonia abstract 폐렴 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103062 898 바이오마커 pneumonias Disease pneumonia abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103063 898 바이오마커 PRISMA Term PRISMA abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103064 898 바이오마커 pro-inflammatory Action pro-inflammatory abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103065 898 바이오마커 provided Action provided abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103066 898 바이오마커 receptor Term receptor abstract 수용기 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103067 898 바이오마커 Reporting Term reporting abstract 보고하기 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103068 898 바이오마커 review Term review abstract 검토 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103069 898 바이오마커 role Term role title abnormality 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103070 898 바이오마커 SARS-CoV-2 Virus sars-cov-2 author 제2형 중증급성호흡기증후군 코로나바이러스 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103071 898 바이오마커 severe COVID-19 Disease severe covid-19 abstract 심한 코비드 -19 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103072 898 바이오마커 severity Term severity abstract 중증도 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103073 898 바이오마커 shown Action shown abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103074 898 바이오마커 significantly Action significantly abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103075 898 바이오마커 SMD Term SMD abstract abnormality 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103076 898 바이오마커 standardized mean difference Term standardized mean difference abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103077 898 바이오마커 subgroup analysis Term subgroup analysis abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103078 898 바이오마커 systematic review Term systematic review title,abstract 체계적인 검토 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103079 898 바이오마커 systematic reviews Term systematic review abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103080 898 바이오마커 the disease Disease the disease abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103081 898 바이오마커 TREM-1 Term trem-1 author None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103082 898 바이오마커 triggering Action triggering title None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103083 898 바이오마커 Viral Term viral abstract 바이러스의 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103084 898 바이오마커 viral infections Symptom viral infection author,abstract 바이러스 감염 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103085 898 바이오마커 Viral pneumonia Disease viral pneumonia abstract 바이러스성 폐렴 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103086 898 바이오마커 Viral pneumonia. Term viral pneumonia author 바이러스성 폐렴 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103087 898 바이오마커 viral pneumonias Disease viral pneumonia abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103088 898 바이오마커 viruses Term virus abstract 바이러스 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103089 898 바이오마커 was performed Action was performed abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103090 898 바이오마커 were expressed Action were expressed abstract None 13782 10.1007/s10787-022-00972-6 Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies Yrna Lorena Matos de Oliveira@@@Ayane de S? Resende@@@Paulo Ricardo Martins-Filho@@@Tatiana Rodrigues de Moura 202206 Meta-Analysis PMC {{{ Abstract }}} !!{{ Background: }} Triggering receptor expressed on myeloid cells-1 (TREM-1) has emerged as an important inflammatory marker of immune response associated with severity and mortality outcomes in infection diseases, including viral pneumonias. !!{{ Aim: }} (1) To evaluate the expression of TREM-1 in patients with COVID-19 and other viral pneumonias compared to healthy individuals; and (2) to analyze the levels of these biomarkers according to disease severity. !!{{ Materials and methods: }} This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed in PubMed, Scopus, Embase, and Google Scholar. Studies were considered eligible if they were observational studies that provided data on the levels of TREM-1 in humans with viral pneumonia compared to healthy controls. The results of the meta-analysis were expressed as standardized mean difference (SMD) and an effect size of 0.8 was considered a large effect. A subgroup analysis was performed according to the disease severity. !!{{ Results: }} Seven studies were included in this systematic review. Four studies included patients with COVID-19 and three analyzed patients with different viruses. The meta-analysis was performed only with patients with COVID-19, which showed increased levels of soluble form of TREM-1 (sTREM-1) among patients with COVID-19 compared to healthy controls (SMD 1.53; 95% CI 0.53-2.52; p < 0.01). No differences were found between patients with mild-to-moderate COVID-19 and healthy controls, but higher levels of sTREM-1 were shown among patients with severe COVID-19 (SMD 1.83; 95% CI 0.77-2.88; p < 0.01). All three studies including patients with other viral pneumonias showed that TREM-1 levels were significantly elevated in infected patients compared with controls. !!{{ Conclusion: }} These findings may provide evidence on the pro-inflammatory role of TREM-1 in these infections, contributing to the inflammatory profile and disease progression. !!{{ Keywords: }} COVID-19; Coronavirus disease-2019; SARS-CoV-2; TREM-1; Viral infections; Viral pneumonia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959072/ 272 0925-4692 Inflammopharmacology Basel ; Boston : Birkha?user.
103091 898 바이오마커 28-day mortality Term 28-day mortality abstract 28 일 사망률 13783 10.1007/s11739-021-02637-8 Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study Tyler Pitre@@@Aaron Jones@@@Johnny Su@@@Wryan Helmeczi@@@Grace Xu@@@Catherine Lee@@@Adib Shamsuddin@@@Adhora Mir@@@Sarah MacGregor@@@MyLinh Duong@@@Terence Ho@@@Marla K Beauchamp@@@Andrew P Costa@@@Rebecca Kruisselbrink@@@COREG Investigators 202109 Article PMC {{{ Abstract }}} !! Inflammatory biomarkers may be associated with disease severity and increased mortality in COVID-19 patients but have not been studied in North American populations. We sought to determine whether a set of commonly ordered inflammatory biomarkers can predict 28-day mortality. We analyzed a multi-centered (four) COVID-19 registry cohort from March 4th to December 7th, 2020. This cohort included COVID-19-positive patients admitted to medical wards or intensive care units. Patients presenting to the emergency department for COVID-19 symptoms and then subsequently discharged were also included. We performed Cox-regression analysis to measure whether commonly used biomarkers were associated with an increased 28-day mortality. Of 336 COVID-19-positive patients, 267 required hospital admission, and 69 were seen in the emergency room and discharged. The median age was 63 years (IQR 80-50) and the female-to-male ratio was 49:51. Derivation of internally validated cut-offs suggested that C-reactive protein ≥ 78.4 mg/L, neutrophil-to-lymphocyte ratio ≥ 6.1, lymphocyte-to-white blood cell ratio < 0.127, and a modified Glasgow prognostic score equal to 2 vs. 1 or 0 were associated with the highest increased risk of 28-day mortality. We provide early estimates of cut-off values for inflammatory biomarkers and indices measured at the time of admission that may be useful to clinicians for predicting 28-day mortality in North American COVID-19 patients. !!{{ Keywords: }} Biomarkers; COVID-19; CRP; NLR; mGPS. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836340/ 173 1828-0447 Internal and Emergency Medicine Milan : Springer.
103093 898 바이오마커 Analysis Term analysis abstract 분석 13783 10.1007/s11739-021-02637-8 Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study Tyler Pitre@@@Aaron Jones@@@Johnny Su@@@Wryan Helmeczi@@@Grace Xu@@@Catherine Lee@@@Adib Shamsuddin@@@Adhora Mir@@@Sarah MacGregor@@@MyLinh Duong@@@Terence Ho@@@Marla K Beauchamp@@@Andrew P Costa@@@Rebecca Kruisselbrink@@@COREG Investigators 202109 Article PMC {{{ Abstract }}} !! Inflammatory biomarkers may be associated with disease severity and increased mortality in COVID-19 patients but have not been studied in North American populations. We sought to determine whether a set of commonly ordered inflammatory biomarkers can predict 28-day mortality. We analyzed a multi-centered (four) COVID-19 registry cohort from March 4th to December 7th, 2020. This cohort included COVID-19-positive patients admitted to medical wards or intensive care units. Patients presenting to the emergency department for COVID-19 symptoms and then subsequently discharged were also included. We performed Cox-regression analysis to measure whether commonly used biomarkers were associated with an increased 28-day mortality. Of 336 COVID-19-positive patients, 267 required hospital admission, and 69 were seen in the emergency room and discharged. The median age was 63 years (IQR 80-50) and the female-to-male ratio was 49:51. Derivation of internally validated cut-offs suggested that C-reactive protein ≥ 78.4 mg/L, neutrophil-to-lymphocyte ratio ≥ 6.1, lymphocyte-to-white blood cell ratio < 0.127, and a modified Glasgow prognostic score equal to 2 vs. 1 or 0 were associated with the highest increased risk of 28-day mortality. We provide early estimates of cut-off values for inflammatory biomarkers and indices measured at the time of admission that may be useful to clinicians for predicting 28-day mortality in North American COVID-19 patients. !!{{ Keywords: }} Biomarkers; COVID-19; CRP; NLR; mGPS. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836340/ 173 1828-0447 Internal and Emergency Medicine Milan : Springer.
상품 미리보기
연락처 및 데이터 관리
판매제공처 홈페이지 판매담당자 연락처 이메일
www.vinea.co.kr (주)비네아 010-8703-2109 bongbong@vinea.co.kr
제약 및 취소환불 규정
제약 및 취소/환불 규정 안내
데이터 상품은 디지털화된 상품의 특성상 반품, 취소, 환불 되지 않으나 데이터의 심각한 오류, 상이한 데이터에 한하여 구매자가 요구하는 경우 환불을 진행할 수 있습니다.
상품 Q&A

※ 본인의 글만 수정이 가능하며, 타인의 글에 댓글을 남길 수 없습니다.
※ 댓글이 달린 글은 수정과 삭제가 불가능합니다.

등록된 글이 없습니다.

닫기버튼
해당 문의 내역을 삭제하시겠습니까?

닫기버튼
해당 문의 내역을 삭제하시겠습니까?